Reverse Transcriptase Inhibitors
Reverse transcriptase inhibitors (RTIs) are a class of antiviral drugs that target the reverse transcriptase enzyme, which is crucial for the replication of retroviruses like HIV. Reverse transcriptase converts viral RNA into DNA, allowing the virus to integrate into the host's genome and replicate. RTIs are designed to inhibit this enzyme, thus blocking the conversion process and preventing the virus from multiplying. There are two main types of RTIs: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), which mimic the natural nucleotides and cause premature chain termination during DNA synthesis, and non-nucleoside reverse transcriptase inhibitors (NNRTIs), which bind to a different site on the reverse transcriptase enzyme and induce conformational changes that inhibit its function. By interfering with viral replication, RTIs help reduce the viral load in patients, improving immune function and delaying the progression of HIV to AIDS.
- Structure
- Product name
- CAS No.
- Molecular formula
- Inquiry
Total:3 Page 1 of 1 1
![DAPIVIRINE,4-[[4-(2,4,6-TRIMETHYLPHENYL)AMINO]PYRIMIDIN-2-YL]AMINO]BENZONITRILE](http://file1.lookchem.com/cas/reactions/2021/07/05/8934631.png)
![4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3, 5 –dimethylbenzonitrile](http://file1.lookchem.com/cas/reactions/2021/07/05/8945855.png)
![4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile](http://file1.lookchem.com/300w/synthetic/2022-01-24-06/9ae97d10-8fd1-462d-801f-95d180487738.png)